EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4 /6 inhibitor in advanced breast cancer

Charlotte K Kindt, Carla L Alves, Sidse Ehmsen, Amalie Kragh, Thomas Reinert, Marianne Vogsen, Annette R Kodahl, Jeanette D Rønlev, Dilan Ardik, Anna L Sørensen, Kirstine Evald, Mia L Clemmensen und 2 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Charlotte K Kindt und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Circulating Tumor DNA, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Academy of Geriatric Cancer Research (AgeCare), Agnes and Poul Friis' Foundation, Fonden til Lægevidenskabens Fremme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy significantly improves outcome for patients with estrogen receptor‐positive (ER+) metastatic breast cancer, but drug resistance and thus disease progression inevitably occur. Herein, we aimed to identify genomic alterations associated with combined CDK4/6i and endocrine therapy resistance, and follow the levels of specific mutations in longitudinal circulating tumor DNA (ctDNA) for early detection of progression. From a cohort of 86 patients with ER+ metastatic breast cancer we performed whole exome sequencing or targeted sequencing of paired tumor ( N = 8) or blood samples ( N = 5) obtained before initiation of combined CDK4/6i and endocrine therapy and at disease progression. Mutations in oncogenic genes at progression were rare, while amplifications of growth‐regulating genes were more frequent. The most frequently acquired alterations observed were PIK3CA and TP53 mutations and PDK1 amplification. Longitudinal ctDNA dynamics of mutant PIK3CA or private mutations revealed increased mutation levels at progression in 8 of 10 patients (80%). Impressively, rising levels of PIK3CA ‐mutated ctDNA were detected 4–17 months before imaging. Our data add to the growing evidence supporting longitudinal ctDNA analysis for real‐time monitoring of CDK4/6i response and early detection of progression in advanced breast cancer. Further, our analysis suggests that amplification of growth‐related genes may contribute to combined CDK4/6i and endocrine therapy resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Circulating Tumor DNACyclin-Dependent Kinase 6Drug Resistance, NeoplasmDisease ProgressionMutationProtein Kinase InhibitorsHumansFemaleMiddle AgedClass I Phosphatidylinositol 3-KinasesAgedAdultReceptors, EstrogenExome SequencingBiomarkers, TumorTumor Suppressor Protein p53

Stichwörter der Autor:innen

CDK4/6 inhibitorctDNAestrogen receptor‐positive breast cancergenomic alterationsresistance

Substanzen

Cyclin-Dependent Kinase 4Circulating Tumor DNACyclin-Dependent Kinase 6CDK4 protein, humanProtein Kinase InhibitorsCDK6 protein, humanPIK3CA protein, humanClass I Phosphatidylinositol 3-KinasesReceptors, EstrogenBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Cancer Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Department of Oncology, Odense University Hospital; Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.
  • Department of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.
  • PentaBase A/S, Odense, Denmark.
  • Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Medicon Village, Lund, Sweden.

ORCID-Profile: Johan Staaf, Henrik J Ditzel

Förderung

  • Academy of Geriatric Cancer Research (AgeCare)
  • Agnes and Poul Friis' Foundation
  • Fonden til Lægevidenskabens Fremme
  • Kræftens Bekæmpelse
  • EUREKA-Eurostars Grant
  • Else and Mogens Wedell-Wedellborgs Foundation
  • Pink Tribute
  • Grosserer L.F. Foghts Foundation

Zitieren

APA

Kindt, C. K., Alves, C. L., Ehmsen, S., Kragh, A., Reinert, T., Vogsen, M., Kodahl, A. R., Rønlev, J. D., Ardik, D., Sørensen, A. L., Evald, K., Clemmensen, M. L., Staaf, J., & Ditzel, H. J. (2024). Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4 /6 inhibitor in advanced breast cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35126

Vancouver

Kindt CK, Alves CL, Ehmsen S, Kragh A, Reinert T, Vogsen M, et al. Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4 /6 inhibitor in advanced breast cancer. International Journal of Cancer. 2024. doi:10.1002/ijc.35126

BibTeX
@article{Kindt2024,
  author = {Kindt, Charlotte K and Alves, Carla L and Ehmsen, Sidse and Kragh, Amalie and Reinert, Thomas and Vogsen, Marianne and Kodahl, Annette R and Rønlev, Jeanette D and Ardik, Dilan and Sørensen, Anna L and Evald, Kirstine and Clemmensen, Mia L and Staaf, Johan and Ditzel, Henrik J},
  title = {Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4 /6 inhibitor in advanced breast cancer},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35126}
}
Kostenlos starten →